Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is progressing its clinical development of LUCID-MS, a proprietary therapy candidate for multiple sclerosis (MS). The company announced that Phase 1 studies in healthy volunteers demonstrated a favorable safety profile and general tolerability, supporting advancement into patient-focused studies. In April 2026, Quantum BioPharma submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for LUCID-MS, paving the way for a planned Phase 2 clinical trial in people living with MS.
LUCID-MS is designed to target demyelination and protect or restore myelin integrity, which is a key underlying mechanism of MS. Unlike existing therapies that primarily rely on immune modulation, LUCID-MS aims to directly address myelin loss and neurodegeneration, potentially offering a differentiated, first-in-class approach. The company is strengthening operational support for the program through a planned partnership with Allucent and engagement with neurological specialists.
Quantum BioPharma is a biopharmaceutical company focused on building a portfolio of innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is advancing LUCID-MS, a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation. In addition to its MS program, Quantum BioPharma invented unbuzzd and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake and royalty payments.
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM. For the full article, visit https://ibn.fm/AUhNl.
